References
- 1. Bureau of Vector Borne Disease. Malaria situation. Nonthaburi:Ministry of Public Health of Thailand, 2008. Available at http://www.thaivbd.org/cms.
- 2. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A. In vivo sensitivity monitoring of mefloquine monotherapy and artesunatemefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006; 11: 211-9.10.1111/j.1365-3156.2005.01557.x
- 3. Suputtamongkol Y, Chindarat S, Silpasakorn S, Chaikachonpatd S, Lim Kimheng, Chanthapakajee K, et al. The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. Am J Trop Med Hyg. 2003; 68:620-3.10.4269/ajtmh.2003.68.620
- 4. Chareonviriyaphap T, Bangs MJ, Ratanatham S. Status of malaria in Thailand. Southeast Asian J Trop Med Public Health. 2000; 31: 225-37.
- 5. Rooney W. Dynamics of multi-drug resistance in Plasmodium falciparum in Thailand. Southeast Asian J Trop Med Public Health. 1992; 23 (Suppl 4): 131-7.
- 6. Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Friday AO, Oguche S, et al., Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria. Malar J. 2008; 7: 172.10.1186/1475-2875-7-172
- 7. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997; 41:1413-22.10.1128/AAC.41.7.1413
- 8. World Health Organization. Management of severe malaria: a practical handbook. Second edition. Geneva: WHO, 2000. Available at http://apps.who.int/malaria/docs/hbsm.pdf.
- 9. Farnert A, Arez AP, Babiker HA, Beck HP, Benito A, Bjorkman A, et al. Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. Trans R Soc Trop Med Hyg. 2001; 95:225-32.10.1016/S0035-9203(01)90175-0
- 10. World Health Organization. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: WHO, 2008. Available at http://www.who.int/malaria/resistance.
- 11. WHO/MAL/82.988. Methods for surveillance of antimalarial drug efficacy. Geneva:WHO. Available at http://www.who.int/malaria/resistance.
- 12. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO/HTM/RBM/2003.50. Geneva:WHO, 2003. Available at http://www.who.int/malaria/resistance.
- 13. World Health Organization. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996-2004. WHO/HTM/MAL/ 2005.110, Geneva:WHO. 2005. Available at http://www.who.int/malaria/resistance.
- 14. World Heath Organization. Guidelines for the treatment of malaria. 1st ed. Geneva, Switzerland. WHO:2006, p. 133-343.